- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02707120
Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis
Randomized, Parallel Groups, Multicenter and Blind to Evaluators Clinical Trial, to Evaluate the Efficacy and Safety of PRGF-Endoret Eye Drops, in Patients With Stage 2 and 3 Neurotrophic Keratitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The goals of treatment in the neurotrophic keratitis are prevent the progression of corneal damage, maintain eye structure and improve the transparency of the cornea. Therapy should be initiated early and based on the clinical stage of the disease because it depends on epithelial state and in the degree of corneal hypoesthesia.
Plasma rich in growth factors (PRGF-Endoret) represent a new technology using autologous proteins, growth factors and biomaterials as therapeutic formulations for different regenerative purposes. Under strict pharmaceutical development, it is possible to develop biologically stable eye drops, which have been shown to be useful for treating diverse ocular surface diseases. PRGF-Endoret eye drops could be an alternative therapy for patients with NK, and thus the objective of this clinical trial is to demonstrate its possible efficacy and its safety in patients with NK in stages 2 and 3.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Gorka Orive, PhD
- Phone Number: 663027696
- Email: gorka.orive@bti-implant.es
Study Locations
-
-
-
Barcelona, Spain
- Instituto de Microcirugía Ocular (IMO)
-
Madrid, Spain
- Hospital Ramón y Cajal
-
-
Asturias
-
Oviedo, Asturias, Spain
- Instituto Oftalmologico Fernandez-Vega
-
-
Bizkaia
-
Bilbao, Bizkaia, Spain
- Instituto Clínico Quirúrgico de Oftalmología (ICQO)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18 or over.
- With neurotrophic keratitis at stages 2 or 3 affecting only one eye.
- Persistent epithelial defect or corneal ulcer of at least 2 weeks duration resistant to one or more traditional non-surgical treatments .
- Corneal sensitivity reduction test in the area of the persistent epithelial defect or corneal ulcer and out of the defect area in at least one corneal quadrant.
- No objective clinical evidence of improvement in the two weeks prior to enrollment.
- Patients who have previously read and signed the informed consent.
Exclusion Criteria:
- Patients with neurotrophic keratitis stages 2 or 3 that affects both eyes.
- With active ocular infection or inflammation not related to the neurotrophic keratitis
- Any other eye disease that requires of topical ocular treatment in the affected eye during study.
- Patients with severe vision loss
- Patients with severe blepharitis and/or severe Meibomian glands disease
- History of eye surgery in the three months prior to enter the study, or patients who plan to undergo surgery.
- Having received previously surgical procedures for the treatment of NK.
- Use of therapeutic contact lenses or for refractive correction during study.
- Patients with punctual occlusion or insertion of punctual plugs previous to the study
- Evidence of corneal ulcer affecting the corneal stroma or cornea perforation.
- Presence of any disorder or ocular or systemic disease that could limit the treatment effectiveness or its evaluation,
- Any need of change (at that time or planned) in the dose of systemic drugs known to disrupt the functioning of the trigeminal nerve
- Known hypersensitivity to any of the procedural compounds (eg. fluoresceine).
- Presence of blood disorders associated with platelet disorders or clotting, or receiving anticoagulants drugs or antiplatelet agents.
- Patients with positive result in one of the serological tests for syphilis, Hepatitis B-C or AIDS I / II.
- Patient in current treatment for their pathology already well managed.
- Use of any investigational drug within 4 weeks prior to the screening visit.
- Pregnant women or intended to be pregnant.
- Participating in another clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PRGF-Endoret eye-drops
|
Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
|
Active Comparator: Artificial tears eye-drops
|
Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of patients with a reduction of corneal defect of >50%
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with a reduction of corneal defect of >50%
Time Frame: 2 weeks
|
2 weeks
|
|
Percentage of patients showing complete healing of the corneal defect
Time Frame: 4 weeks
|
4 weeks
|
|
Percentage of patients showing complete healing of the corneal defect
Time Frame: 2 weeks
|
2 weeks
|
|
Measurement of the depth of the corneal defect (mm)
Time Frame: 2 and 4 weeks
|
2 and 4 weeks
|
|
Changes in percentage in Best corrected visual acuity (BCVA LogMAR)
Time Frame: 2 and 4 weeks
|
2 and 4 weeks
|
|
Ocular pain with VAS scale
Time Frame: 2 and 4 weeks
|
2 and 4 weeks
|
|
Osmolarity of lacrimal film
Time Frame: 2 and 4 weeks
|
2 and 4 weeks
|
|
Measurement of treatment tolerance
Time Frame: 2 and 4 weeks
|
Measurement of treatment tolerance with a 0 4 score
|
2 and 4 weeks
|
Adverse events
Time Frame: 2 and 4 weeks
|
Percentage of adverse event occurrence
|
2 and 4 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTI-011-EC/15/QUER
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurotrophic Keratitis
-
Dompé Farmaceutici S.p.ARecruitingNeurotrophic KeratitisUnited States
-
University of California, Los AngelesRecruiting
-
University of AlbertaWithdrawn
-
Sight Medical Doctors PLLCDompé, US, Inc.RecruitingNeurotrophic Keratitis | Neurotrophic Ulcer | Neurotrophic Corneal Ulcer | Neurotrophic KeratoconjunctivitisUnited States
-
Recordati Rare DiseasesSyneos HealthRecruitingNeurotrophic KeratitisUnited Kingdom, Spain, Italy, United States, Germany, France, Hungary
-
Dompé Farmaceutici S.p.ACompletedNeurotrophic KeratitisUnited States
-
Stanford UniversityCompleted
-
BRIM Biotechnology Inc.Not yet recruiting
-
Claris Biotherapeutics, Inc.RecruitingNeurotrophic KeratitisUnited States, Canada
-
Dompé Farmaceutici S.p.ADompé USCompletedNeurotrophic KeratitisUnited States
Clinical Trials on PRGF-Endoret
-
Fundación Eduardo AnituaRecruiting
-
Universidad de GranadaBTI Biotechnology InstituteActive, not recruiting
-
Queen Mary University of LondonRecruiting
-
Queen Mary University of LondonActive, not recruiting
-
Biotechnology Institute IMASDUnknownAndrogenetic AlopeciaSpain
-
Fundación Eduardo AnituaRecruiting
-
Sara Rafael FernandezCompletedInfertility | Infertility, FemaleSpain
-
Fundación Eduardo AnituaCompletedPost-Extraction Sockets HealingSpain
-
Ain Shams UniversityCompletedAlveolar Socket Preservations
-
Price Vision GroupNot yet recruitingCorneal Edema | Fuchs' Endothelial DystrophyUnited States